 PALO ALTO, Calif., Nov. 17, 2020 PRNewswire -- Kodiak Sciences Inc. Nasdaq: KOD, a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an underwritten... 